{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T20:49:57Z","timestamp":1787690997927,"version":"build-2784847793"},"reference-count":73,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,9,27]],"date-time":"2021-09-27T00:00:00Z","timestamp":1632700800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:p><jats:bold>Aims:<\/jats:bold> To determine real-life biologic\/targeted synthetic disease-modifying anti-rheumatic drug (b\/tsDMARD) retention rates in rheumatoid arthritis (RA), psoriatic arthritis (PsA), and ankylosing spondylitis (AS), explore reasons for switching and to compare results to previously published data.<\/jats:p><jats:p><jats:bold>Methods:<\/jats:bold> Time-to-event analysis for mean treatment duration (estimated as the Restricted Mean Survival Time), b\/tsDMARD failure, and b\/tsDMARDs switching was performed for 230 patients (<jats:italic>n<\/jats:italic> = 147 RA, 46 PsA, 37 AS) who commenced their first b\/tsDMARD between 2008 and 2018. Patients were managed in a dedicated \u201cbiologics\u201d clinic in a tertiary hospital; the choice of b\/tsDMARD was clinician driven based on medical factors and patient preferences. The effect of covariates on switching risk was analysed by a conditional risk-set Cox proportional-hazards model. Treatment retention data was compared to a historical analysis (2002\u20132008).<\/jats:p><jats:p><jats:bold>Results:<\/jats:bold> The proportions remaining on treatment (retention) were similar, throughout follow-up, for the first, second and third b\/tsDMARDs across all patients (<jats:italic>p<\/jats:italic> = 0.46). When compared to RA patients, the risk of b\/tsDMARD failure was halved in PsA patients [Hazard Ratio (HR) = 0.50], but no different in AS patients (HR = 1.0). The respective restricted mean (95%CI) treatment durations, estimated at 5 years of follow-up, were 3.1 (2.9, 3.4), 4.1 (3.7, 4.6), and 3.3 (2.8, 3.9) years, for RA, PsA, and AS, respectively. Age, gender, disease duration, smoking status and the use of concomitant csDMARDS were not associated with the risk of bDMARD failure. The most common reasons for switching in the first and subsequent years were secondary (<jats:italic>n<\/jats:italic> = 62) and primary (<jats:italic>n<\/jats:italic> = 35) failure. Comparison with historical data indicated no substantive differences in switching of the first biologic for RA and PsA.<\/jats:p><jats:p><jats:bold>Conclusion:<\/jats:bold> Similar retention rates of the second and third compared to the first b\/tsDMARD in RA, PsA, and AS support a strategy of differential b\/tsDMARDs use informed by patient presentation. Despite greater availability of b\/tsDMARDs with differing mechanisms of action, retention rates of the first b\/tsDMARD remain similar to previous years.<\/jats:p>","DOI":"10.3389\/fmed.2021.708168","type":"journal-article","created":{"date-parts":[[2021,9,27]],"date-time":"2021-09-27T07:11:42Z","timestamp":1632726702000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":15,"title":["Real-Life Retention Rates and Reasons for Switching of Biological DMARDs in Rheumatoid Arthritis, Psoriatic Arthritis, and Ankylosing Spondylitis"],"prefix":"10.3389","volume":"8","author":[{"given":"Vandana","family":"Bhushan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Lester","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liz","family":"Briggs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raif","family":"Hijjawi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E. Michael","family":"Shanahan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eliza","family":"Pontifex","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jem","family":"Ninan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Hill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fin","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Walker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fiona","family":"Goldblatt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mihir D.","family":"Wechalekar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,9,27]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1016\/j.ebiom.2016.08.024","article-title":"Rheumatoid arthritis patients after initiation of a new biologic agent: trajectories of disease activity in a large multinational cohort study","volume":"11","author":"Courvoisier","year":"2016","journal-title":"EBioMedicine."},{"key":"B2","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1186\/1471-2474-15-290","article-title":"The perplexity of prescribing and switching of biologic drugs in rheumatoid arthritis: a UK regional audit of practice","volume":"15","author":"Blake","year":"2014","journal-title":"BMC Musculoskelet Disord."},{"key":"B3","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1186\/s41927-019-0097-0","article-title":"Factors that influence rheumatologists' anti-tumor necrosis factor alpha prescribing decisions: a qualitative study","volume":"3","author":"Gavan","year":"2019","journal-title":"BMC Rheumatol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1007\/s10354-010-0796-z","article-title":"Comparison of different biologic agents in patients with rheumatoid arthritis after failure of the first biologic therapy","volume":"160","author":"Strehblow","year":"2010","journal-title":"Wien Med Wochenschr."},{"key":"B5","doi-asserted-by":"publisher","first-page":"R66","DOI":"10.1186\/ar1933","article-title":"Clinical and functional remission: even though biologics are superior to conventional DMARDs overall success rates remain low\u2013results from RABBIT, the German biologics register","volume":"8","author":"Listing","year":"2006","journal-title":"Arthritis Res Ther."},{"key":"B6","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1186\/s13075-019-1917-8","article-title":"Persistence rates of abatacept and TNF inhibitors used as first or second biologic DMARDs in the treatment of rheumatoid arthritis: 9 years of experience from the Rhumadata(R) clinical database and registry","volume":"21","author":"Choquette","year":"2019","journal-title":"Arthritis Res Ther."},{"key":"B7","doi-asserted-by":"publisher","first-page":"1747","DOI":"10.1007\/s10067-017-3712-8","article-title":"Real-life 10-year retention rate of first-line anti-TNF drugs for inflammatory arthritides in adult- and juvenile-onset populations: similarities and differences","volume":"36","author":"Favalli","year":"2017","journal-title":"Clin Rheumatol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"1172","DOI":"10.1001\/jama.2016.13512","article-title":"Non-TNF-targeted biologic vs. a second anti-TNF drug to treat rheumatoid arthritis in patients with insufficient response to a first anti-TNF drug: a randomized clinical trial","volume":"316","author":"Gottenberg","year":"2016","journal-title":"JAMA"},{"key":"B9","doi-asserted-by":"publisher","first-page":"2763","DOI":"10.1016\/S0140-6736(16)31651-8","article-title":"Head-to-head comparison of certolizumab pegol versus adalimumab in rheumatoid arthritis: 2-year efficacy and safety results from the randomised EXXELERATE study","volume":"388","author":"Smolen","year":"2016","journal-title":"Lancet."},{"key":"B10","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1016\/j.autrev.2017.10.002","article-title":"The management of first-line biologic therapy failures in rheumatoid arthritis: current practice and future perspectives","volume":"16","author":"Favalli","year":"2017","journal-title":"Autoimmun Rev."},{"key":"B11","first-page":"S28","article-title":"Use of data from multiple registries in studying biologic discontinuation: challenges and opportunities","volume":"31","author":"Yoshida","year":"2013","journal-title":"Clin Exp Rheumatol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"vii54","DOI":"10.1093\/rheumatology\/key109","article-title":"Randomized controlled trials and real-world data: differences and similarities to untangle literature data","volume":"57","author":"Monti","year":"2018","journal-title":"Rheumatology (Oxford)"},{"key":"B13","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/j.semarthrit.2010.03.003","article-title":"A comparison of patient characteristics and outcomes in selected European and U.S. rheumatoid arthritis registries","volume":"40","author":"Curtis","year":"2010","journal-title":"Semin Arthritis Rheum"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1478","DOI":"10.1002\/acr.22860","article-title":"Generalizability of patients with rheumatoid arthritis in biologic agent clinical trials","volume":"68","author":"Vashisht","year":"2016","journal-title":"Arthritis Care Res (Hoboken)."},{"key":"B15","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1136\/annrheumdis-2019-216655","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update","volume":"79","author":"Smolen","year":"2020","journal-title":"Ann Rheum Dis."},{"key":"B16","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1186\/s12891-015-0636-9","article-title":"Prognostic factors for abatacept retention in patients who received at least one prior biologic agent: an interim analysis from the observational, prospective ACTION study","volume":"16","author":"Nusslein","year":"2015","journal-title":"BMC Musculoskelet Disord."},{"key":"B17","doi-asserted-by":"publisher","first-page":"2174","DOI":"10.1136\/annrheumdis-2014-205325","article-title":"Rheumatoid arthritis secondary non-responders to TNF can attain an efficacious and safe response by switching to certolizumab pegol: a phase IV, randomised, multicentre, double-blind, 12-week study, followed by a 12-week open-label phase","volume":"73","author":"Schiff","year":"2014","journal-title":"Ann Rheum Dis."},{"key":"B18","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1016\/S0140-6736(09)60506-7","article-title":"Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor alpha inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial","volume":"374","author":"Smolen","year":"2009","journal-title":"Lancet."},{"key":"B19","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1186\/s13075-015-0841-9","article-title":"Twenty-eight-week results from the REALISTIC phase IIIb randomized trial: efficacy, safety and predictability of response to certolizumab pegol in a diverse rheumatoid arthritis population","volume":"17","author":"Weinblatt","year":"2015","journal-title":"Arthritis Res Ther."},{"key":"B20","doi-asserted-by":"publisher","first-page":"707","DOI":"10.2147\/CEOR.S115706","article-title":"Treatment effectiveness and treatment patterns among rheumatoid arthritis patients after switching from a tumor necrosis factor inhibitor to another medication","volume":"8","author":"Bonafede","year":"2016","journal-title":"Clinicoecon Outcomes Res."},{"key":"B21","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/j.semarthrit.2017.03.008","article-title":"Second-line biologic therapy optimization in rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis","volume":"47","author":"Cantini","year":"2017","journal-title":"Semin Arthritis Rheum."},{"key":"B22","doi-asserted-by":"publisher","first-page":"2422","DOI":"10.1007\/s12325-017-0617-5","article-title":"Treatment persistence and healthcare costs among patients with rheumatoid arthritis changing biologics in the USA","volume":"34","author":"Chastek","year":"2017","journal-title":"Adv Ther."},{"key":"B23","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1136\/annrheumdis-2013-203993","article-title":"Rituximab versus an alternative TNF inhibitor in patients with rheumatoid arthritis who failed to respond to a single previous TNF inhibitor: SWITCH-RA, a global, observational, comparative effectiveness study","volume":"74","author":"Emery","year":"2015","journal-title":"Ann Rheum Dis."},{"key":"B24","doi-asserted-by":"publisher","first-page":"1936","DOI":"10.1007\/s12325-017-0578-8","article-title":"Treatment persistence and clinical outcomes of tumor necrosis factor inhibitor cycling or switching to a new mechanism of action therapy: real-world observational study of rheumatoid arthritis patients in the United States with prior tumor necrosis factor inhibitor therapy","volume":"34","author":"Wei","year":"2017","journal-title":"Adv Ther."},{"key":"B25","doi-asserted-by":"publisher","first-page":"1664","DOI":"10.1093\/rheumatology\/keu158","article-title":"Survival on treatment with second-line biologic therapy: a cohort study comparing cycling and swap strategies","volume":"53","author":"Favalli","year":"2014","journal-title":"Rheumatology (Oxford)."},{"key":"B26","doi-asserted-by":"publisher","first-page":"1787","DOI":"10.1007\/s10067-015-3066-z","article-title":"Slovenian R. Retention of the second-line biologic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis failing one tumor necrosis factor alpha inhibitor: data from the BioRxsi registry","volume":"34","author":"Rotar","year":"2015","journal-title":"Clin Rheumatol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1186\/s13075-015-0776-1","article-title":"Comparative effectiveness and safety of rituximab versus subsequent anti-tumor necrosis factor therapy in patients with rheumatoid arthritis with prior exposure to anti-tumor necrosis factor therapies in the United States Corrona registry","volume":"17","author":"Harrold","year":"2015","journal-title":"Arthritis Res Ther."},{"key":"B28","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1007\/s12272-014-0337-1","article-title":"Comparative effectiveness of cycling of tumor necrosis factor-alpha (TNF-alpha) inhibitors versus switching to non-TNF biologics in rheumatoid arthritis patients with inadequate response to TNF-alpha inhibitor using a Bayesian approach","volume":"37","author":"Kim","year":"2014","journal-title":"Arch Pharm Res."},{"key":"B29","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.1002\/acr.21663","article-title":"Rituximab or a second anti-tumor necrosis factor therapy for rheumatoid arthritis patients who have failed their first anti-tumor necrosis factor therapy? Comparative analysis from the British Society for Rheumatology Biologics Register","volume":"64","author":"Soliman","year":"2012","journal-title":"Arthritis Care Res (Hoboken)."},{"key":"B30","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/s13075-020-02380-z","article-title":"Long-term remission and biologic persistence rates: 12-year real-world data","volume":"23","author":"Murray","year":"2021","journal-title":"Arthritis Res Ther."},{"key":"B31","doi-asserted-by":"publisher","first-page":"420759","DOI":"10.1155\/2009\/420759","article-title":"Biologic agents-a panacea for inflammatory arthritis or not?","volume":"2009","author":"Ninan","year":"2009","journal-title":"Int J Rheumatol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1093\/biomet\/68.2.373","article-title":"On the regression analysis of multivariate failure time data","volume":"68","author":"Prentice","year":"1981","journal-title":"Biometrika."},{"key":"B33","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1111\/biom.12384","article-title":"On therestricted mean survival time curve in survival analysis","volume":"72","author":"Zhao","year":"2016","journal-title":"Biometrics."},{"key":"B34","volume-title":"STPM2: Stata Module to Estimate Flexible Parametric Survival Models Statistical Software Components S457128","author":"Lambert","year":"2010"},{"key":"B35","article-title":"Standardized survival curves and related measures from flexible survival parametric models","volume-title":"London Stata Conference; 6-7th September 2018: Stata Users Group","author":"Lambert","year":"2018"},{"key":"B36","volume-title":"STCOMPET: Stata Module to Generate Cumulative Incidence in Presence of Competing Events. Statistical Software Components S431301","author":"Coviello","year":"2003"},{"key":"B37","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1002\/art.10456","article-title":"Physician treatment preferences in rheumatoid arthritis of differing disease severity and activity: the impact of cost on first-line therapy","volume":"47","author":"Erkan","year":"2002","journal-title":"Arthritis Rheum."},{"key":"B38","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1007\/s40744-020-00203-w","article-title":"Biologic disease-modifying antirheumatic drug prescription patterns for rheumatoid arthritis among United States Physicians","volume":"7","author":"Sullivan","year":"2020","journal-title":"Rheumatol Ther."},{"key":"B39","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1007\/s40744-020-00211-w","article-title":"Biologic disease-modifying antirheumatic drug prescription patterns among rheumatologists in Europe and Japan","volume":"7","author":"Sullivan","year":"2020","journal-title":"Rheumatol Ther."},{"key":"B40","doi-asserted-by":"publisher","first-page":"871-81","DOI":"10.1016\/j.jaad.2013.12.018","article-title":"Patient perspectives in the management of psoriasis: results from the population-based multinational assessment of psoriasis and psoriatic arthritis survey","volume":"70","author":"Lebwohl","year":"2014","journal-title":"J Am Acad Dermatol"},{"key":"B41","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1093\/rheumatology\/kep354","article-title":"Patient preferences in the choice of anti-TNF therapies in rheumatoid arthritis. Results from a questionnaire survey (RIVIERA study)","volume":"49","author":"Scarpato","year":"2010","journal-title":"Rheumatology (Oxford)."},{"key":"B42","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1185\/03007995.2013.786693","article-title":"Dosing patterns of three tumor necrosis factor blockers among patients with rheumatoid arthritis in a large United States managed care population","volume":"29","author":"Fisher","year":"2013","journal-title":"Curr Med Res Opin."},{"key":"B43","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1007\/s12325-012-0037-5","article-title":"Treatment patterns in the first year after initiating tumor necrosis factor blockers in real-world settings","volume":"29","author":"Bonafede","year":"2012","journal-title":"Adv Ther."},{"key":"B44","doi-asserted-by":"publisher","first-page":"259","DOI":"10.3111\/13696998.2014.893241","article-title":"Switching of biologic disease modifying anti-rheumatic drugs in patients with rheumatoid arthritis in a real world setting","volume":"17","author":"Meissner","year":"2014","journal-title":"J Med Econ."},{"key":"B45","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1111\/j.1524-4733.2010.00764.x","article-title":"Adherence, discontinuation, and switching of biologic therapies in medicaid enrollees with rheumatoid arthritis","volume":"13","author":"Li","year":"2010","journal-title":"Value Health."},{"key":"B46","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1016\/j.semarthrit.2013.07.011","article-title":"Comparative effectiveness and survival of infliximab, adalimumab, and etanercept for rheumatoid arthritis patients in the Hellenic Registry of Biologics: low rates of remission and 5-year drug survival","volume":"43","author":"Flouri","year":"2014","journal-title":"Semin Arthritis Rheum."},{"key":"B47","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1007\/s00296-015-3348-4","article-title":"Treatment persistence among patients with rheumatoid disease (RA, AS, PsA) treated with subcutaneous biologics in Germany","volume":"36","author":"Lyu","year":"2016","journal-title":"Rheumatol Int."},{"key":"B48","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1007\/s10067-017-3593-x","article-title":"Impact of prior biologic use on persistence of treatment in patients with psoriatic arthritis enrolled in the US Corrona registry","volume":"36","author":"Harrold","year":"2017","journal-title":"Clin Rheumatol."},{"key":"B49","doi-asserted-by":"publisher","first-page":"R94","DOI":"10.1186\/ar3021","article-title":"Remission in psoriatic arthritis: is it possible and how can it be predicted?","volume":"12","author":"Saber","year":"2010","journal-title":"Arthritis Res Ther."},{"key":"B50","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.3899\/jrheum.101142","article-title":"Persistence with anti-tumor necrosis factor therapies in patients with rheumatoid arthritis: observations from the RADIUS registry","volume":"38","author":"Markenson","year":"2011","journal-title":"J Rheumatol."},{"key":"B51","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1186\/s12891-017-1684-0","article-title":"Drug survival of second biological DMARD therapy in patients with rheumatoid arthritis: a retrospective non-interventional cohort analysis","volume":"18","author":"Wilke","year":"2017","journal-title":"BMC Musculoskelet Disord."},{"key":"B52","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1002\/art.24463","article-title":"Comparison of drug retention rates and causes of drug discontinuation between anti-tumor necrosis factor agents in rheumatoid arthritis","volume":"61","author":"Du Pan","year":"2009","journal-title":"Arthritis Rheum."},{"key":"B53","doi-asserted-by":"publisher","first-page":"1840","DOI":"10.1136\/annrheumdis-2012-203018","article-title":"Switching between TNF inhibitors in psoriatic arthritis: data from the NOR-DMARD study","volume":"72","author":"Fagerli","year":"2013","journal-title":"Ann Rheum Dis."},{"key":"B54","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.1002\/art.37876","article-title":"Clinical response, drug survival, and predictors thereof among 548 patients with psoriatic arthritis who switched tumor necrosis factor alpha inhibitor therapy: results from the Danish Nationwide DANBIO Registry","volume":"65","author":"Glintborg","year":"2013","journal-title":"Arthritis Rheum."},{"key":"B55","doi-asserted-by":"publisher","first-page":"e000155","DOI":"10.1136\/rmdopen-2015-000155","article-title":"Discontinuation rates of biologics in patients with rheumatoid arthritis: are TNF inhibitors different from non-TNF inhibitors?","volume":"1","author":"Ramiro","year":"2015","journal-title":"RMD Open."},{"key":"B56","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1093\/rheumatology\/kev374","article-title":"Rate of discontinuation and drug survival of biologic therapies in rheumatoid arthritis: a systematic review and meta-analysis of drug registries and health care databases","volume":"55","author":"Souto","year":"2016","journal-title":"Rheumatology (Oxford)."},{"key":"B57","doi-asserted-by":"publisher","first-page":"e021447","DOI":"10.1136\/bmjopen-2017-021447","article-title":"Comparative effectiveness of first-line biological monotherapy use in rheumatoid arthritis: a retrospective analysis of the RECord-linkage On Rheumatic Diseases study on health care administrative databases","volume":"8","author":"Silvagni","year":"2018","journal-title":"BMJ Open."},{"key":"B58","doi-asserted-by":"publisher","first-page":"2272","DOI":"10.1002\/art.24638","article-title":"Golimumab, a human anti-tumor necrosis factor alpha monoclonal antibody, injected subcutaneously every four weeks in methotrexate-naive patients with active rheumatoid arthritis: twenty-four-week results of a phase III, multicenter, randomized, double-blind, placebo-controlled study of golimumab before methotrexate as first-line therapy for early-onset rheumatoid arthritis","volume":"60","author":"Emery","year":"2009","journal-title":"Arthritis Rheum."},{"key":"B59","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1016\/S0140-6736(04)15640-7","article-title":"Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial","volume":"363","author":"Klareskog","year":"2004","journal-title":"Lancet."},{"key":"B60","doi-asserted-by":"publisher","first-page":"1140","DOI":"10.1093\/rheumatology\/kem072","article-title":"The efficacy of inhibiting tumour necrosis factor alpha and interleukin 1 in patients with rheumatoid arthritis: a meta-analysis and adjusted indirect comparisons","volume":"46","author":"Nixon","year":"2007","journal-title":"Rheumatology (Oxford)."},{"key":"B61","doi-asserted-by":"publisher","first-page":"2563","DOI":"10.1093\/rheumatology\/kez671","article-title":"Is background methotrexate advantageous in extending TNF inhibitor drug survival in elderly patients with rheumatoid arthritis? An analysis of the British Society for Rheumatology Biologics Register","volume":"59","author":"Bechman","year":"2020","journal-title":"Rheumatology (Oxford)."},{"key":"B62","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1177\/2040622312466908","article-title":"Tocilizumab in rheumatoid arthritis: efficacy, safety and its place in therapy","volume":"4","author":"Kaneko","year":"2013","journal-title":"Ther Adv Chronic Dis."},{"key":"B63","doi-asserted-by":"publisher","first-page":"1276","DOI":"10.1136\/annrheumdis-2017-212845","article-title":"Comparative effectiveness of tocilizumab versus TNF inhibitors as monotherapy or in combination with conventional synthetic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis after the use of at least one biologic disease-modifying antirheumatic drug: analyses from the pan-European TOCERRA register collaboration","volume":"77","author":"Lauper","year":"2018","journal-title":"Ann Rheum Dis."},{"key":"B64","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.1093\/rheumatology\/kez021","article-title":"Retention of tocilizumab with and without methotrexate during maintenance therapy for rheumatoid arthritis: the ACTRA-RI cohort study","volume":"58","author":"Mori","year":"2019","journal-title":"Rheumatology (Oxford)."},{"key":"B65","doi-asserted-by":"publisher","first-page":"253","DOI":"10.7326\/0003-4819-159-4-201308200-00006","article-title":"Tofacitinib in combination with nonbiologic disease-modifying antirheumatic drugs in patients with active rheumatoid arthritis: a randomized trial","volume":"159","author":"Kremer","year":"2013","journal-title":"Ann Intern Med."},{"key":"B66","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1002\/art.37816","article-title":"Tofacitinib (CP-690,550) in patients with rheumatoid arthritis receiving methotrexate: twelve-month data from a twenty-four-month phase III randomized radiographic study","volume":"65","author":"van der Heijde","year":"2013","journal-title":"Arthritis Rheum."},{"key":"B67","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1093\/rheumatology\/keaa393","article-title":"The impact of seropositivity on the effectiveness of biologic anti-rheumatic agents: results from a collaboration of 16 registries","volume":"60","author":"Courvoisier","year":"2021","journal-title":"Rheumatology (Oxford)."},{"key":"B68","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1136\/ard.2007.085696","article-title":"doctors S. The effectiveness of leflunomide as a co-therapy of tumour necrosis factor inhibitors in rheumatoid arthritis: a population-based study","volume":"68","author":"Finckh","year":"2009","journal-title":"Ann Rheum Dis."},{"key":"B69","doi-asserted-by":"publisher","first-page":"1346","DOI":"10.1002\/art.39595","article-title":"Brief report: association of rheumatoid factor and anti-citrullinated protein antibody positivity with better effectiveness of abatacept: results from the Pan-European registry analysis","volume":"68","author":"Gottenberg","year":"2016","journal-title":"Arthritis Rheumatol."},{"key":"B70","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3109\/03009742.2011.599073","article-title":"The effect of smoking on response and drug survival in rheumatoid arthritis patients treated with their first anti-TNF drug","volume":"41","author":"Soderlin","year":"2012","journal-title":"Scand J Rheumatol."},{"key":"B71","first-page":"926","article-title":"High rates of stopping or switching biological medications in veterans with rheumatoid arthritis","volume":"27","author":"Oei","year":"2009","journal-title":"Clin Exp Rheumatol."},{"key":"B72","first-page":"96","article-title":"Clinical relevance of switching to a second tumour necrosis factor-alpha inhibitor after discontinuation of a first tumour necrosis factor-alpha inhibitor in rheumatoid arthritis: a systematic literature review and meta-analysis","volume":"29","author":"Remy","year":"2011","journal-title":"Clin Exp Rheumatol."},{"key":"B73","doi-asserted-by":"publisher","first-page":"1672","DOI":"10.1002\/acr.20643","article-title":"Thresholds in disease activity for switching biologics in rheumatoid arthritis patients: experience from a large US cohort","volume":"63","author":"Zhang","year":"2011","journal-title":"Arthritis Care Res (Hoboken)."}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2021.708168\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,27]],"date-time":"2021-09-27T07:11:46Z","timestamp":1632726706000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2021.708168\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,27]]},"references-count":73,"alternative-id":["10.3389\/fmed.2021.708168"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2021.708168","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,27]]},"article-number":"708168"}}